Part,  Chapter, Paragraph

  1    -,     1            |             Narrowing the Health gap”;~b) in 1996, “The State of
  2   II,     4.  3        |     Sustainable Progress and Policies. B. Marin and A. Zaidi. Aldershot -
  3   II,     5.  1.  1    |            average (2001-2003), EU27B) Men.~ ~ ~ ~Table 5.1.1.
  4   II,     5.  1.  1    |               disease, i.e., hepatitis B and C virus (HBV and HCV)
  5   II,     5.  2.  6    |               1839.~Robinson JG, Smith B, Maheshwari N, Schrott H (
  6   II,     5.  2.  7    |             1231–48.~Sarti C, Stegmayr B, Tolonen H, MAhonen M, Tuomilehto
  7   II,     5.  2.  7    |                Q 41(3-4):155178.~Unal B, Critchley JA, Fidan D,
  8   II,     5.  3.  5    |               standard) by sex in 2006 B) Women~ ~Figure 5.3.2a.
  9   II,     5.  3.  5    |              European standard) by sex B) Women~ ~ ~Figure 5.3.3a.
 10   II,     5.  3.  5    |               standard) by sex in 2006 B) Women~ ~Figure 5.3.4a.
 11   II,     5.  3.  5    |              European standard) by sex B) Women~ ~Stomach Cancer (
 12   II,     5.  3.  5    |               standard) by sex in 2006 B) Women~ ~Figure 5.3.6a.
 13   II,     5.  3.  5    |              European standard) by sex B) Women~ ~Figure 5.3.7a.
 14   II,     5.  3.  5    |               standard) by sex in 2006 B) Women~ ~Figure 5.3.8a.
 15   II,     5.  3.  5    |              European standard) by sex B) Women~ ~Colorectal Cancer (
 16   II,     5.  3.  5    |               standard) by sex in 2006 B) Women~ ~Figure 5.3.10a.
 17   II,     5.  3.  5    |              European standard) by sex B) Women~ ~Figure 5.3.11a.
 18   II,     5.  3.  5    |               standard) by sex in 2006 B) Women~ ~Figure 5.3.12a.
 19   II,     5.  3.  5    |              European standard) by sex B) Women~ ~ ~Lung Cancer (
 20   II,     5.  3.  5    |               standard) by sex in 2006 B) Women~ ~Figure 5.3.14a.
 21   II,     5.  3.  5    |              European standard) by sex B) Women~ ~Figure 5.3.15a.
 22   II,     5.  3.  5    |               standard) by sex in 2006 B) Women~ ~Figure 5.3.16a.
 23   II,     5.  3.  5    |              European standard) by sex B) Women~ ~Female Breast Cancer (
 24   II,     5.  3.  6    |               up to 31st December 1999 B) Women~ ~Countries fell
 25   II,     5.  3.  6    |               up to 31st December 1999 B) Women~ ~5-year colorectal
 26   II,     5.  3.  6    |               up to 31st December 1999 B) Women~ ~Survival for lung
 27   II,     5.  3.  6    |               up to 31st December 1999 B) Women~ ~The prognosis for
 28   II,     5.  3.  9    |             Inst 94:606-616.~ ~Jonsson B, Wilking N (2007): Summary.
 29   II,     5.  4.  8    |           Pages S215 – S219~Carstensen B, Kristensen JK, Ottosen
 30   II,     5.  4.  8    |                J, Nilsson PM, Eliasson B; Steering Committee of the
 31   II,     5.  4.  8    |              Pract 61(4):680-3~Jönsson B (2002), CODE-2 Advisory
 32   II,     5.  5.  1    |           Longevity Center.~ ~Kennelly B (2007). The economic cost
 33   II,     5.  5.  2    |                Eastern Europe (Regions B and C)23. ~ ~Apart from
 34   II,     5.  5.  2(23)|                               The EURO B category included countries
 35   II,     5.  5.  2    |                December 2007)~ ~Cooper B (2002): Thinking preventively
 36   II,     5.  5.  3    |              Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J (
 37   II,     5.  5.  3    |               502-8.~Buizza C, Schulze B, Bertocchi E, Rossi G, Ghilardi
 38   II,     5.  5.  3    |               D, Bingefors K, Widerlöv B (2007): Mortality among
 39   II,     5.  5.  3    |            Saxena S, Levav I, Saraceno B (2004): The treatment gap
 40   II,     5.  5.  3    |                M, Wahlbeck K), Section B, p. 257-333, 2007.~htt df~
 41   II,     5.  5.  3    |                 Harris EC, Barraclough B (1997): Suicide as an outcome
 42   II,     5.  5.  3    |             structure, ethnic origin; (b) the capability to detect
 43   II,     5.  5.  3    |               of disease progression, (b) progressive-relapsing MS (
 44   II,     5.  5.  3    |                457.~Celius EG, Vandvik B (2001): Multiple sclerosis
 45   II,     5.  5.  3    |               48: 9194.~Koncan-Vracko B (1994): Epidemiological
 46   II,     5.  5.  3    |                u T, eaManceau E, Lucas B, Lemesle M, Urbinelli R,
 47   II,     5.  5.  3    |              Med 343;938-952.~Peterlin B, Ristic S, Sepcic J, et
 48   II,     5.  5.  3    |              227231.~Poser S, Stickel B, Krtsch U, Burckhardt D,
 49   II,     5.  5.  3    |               U, Burckhardt D, Nordman B (1989): Increasing incidence
 50   II,     5.  5.  3    |    continuously ageing population, and b) will be increasingly dominated
 51   II,     5.  5.  3    |              Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J (
 52   II,     5.  5.  3    |      Koehne-Volland R, Szucs T, Rathay B, Scholz E, Oertel WH (1998):
 53   II,     5.  5.  3    |                M, Machat O, Bornschein B, von Campenhausen S, Berger
 54   II,     5.  5.  3    |           Sutcliffe RL, Prior R, Mawby B, McQuillan WJ (1985): Parkinson’
 55   II,     5.  5.  3    |             Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio
 56   II,     5.  6.  2    |            Health)~· Woolf AD, Pfleger B Burden of Osteoporosis and
 57   II,     5.  6.  3    |             Netherlands~ ~Figure 5.6.2.b Prevalence of self reported
 58   II,     5.  6.  3    |              of radiographic OA by age B) Women~ ~Determinants, risk
 59   II,     5.  6.  6    |                 Petersson IF, Svensson B, Jacobsson LT (2001): Chronic
 60   II,     5.  6.  6    |               Lancet 353:878-882~Combe B, Landewe R, Lukas C, Bolosiu
 61   II,     5.  6.  6    |           Gabriel KR, Lequesne M, Amor B (1992): Longitudinal radiologic
 62   II,     5.  6.  6    |               Jacobson L. and Lindgren B (1996): Vad kostar sjukdomarna? (
 63   II,     5.  6.  6    |        Petterson C, De Laet C, Jonsson B (2004): Mortality after
 64   II,     5.  6.  6    |             Oden A, De Laet C, Jonsson B, Dawson A (2002): Ten-year
 65   II,     5.  6.  6    |             Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000):
 66   II,     5.  6.  6    |        Available at URL: htt ~ ~Natvig B, Nessiøy I, Bruusgaard D,
 67   II,     5.  6.  6    |               1141~Ollier WE, Harrison B, Symmons D (2001) What is
 68   II,     5.  6.  6    |                197~Symmons D, Harrison B (2000): Early inflammatory
 69   II,     5.  6.  6    |                 Mathers C, and Pfleger B (2003): Global Burden of
 70   II,     5.  6.  6    |                89-95~Woolf AD, Pfleger B (2005): Burden of osteoporosis
 71   II,     5.  6.  6    |               347~Woolf AD and Pfleger B (2003): Burden of Major
 72   II,     5.  7.  3    |            Germany (Tables 5.7.6 A and B). It increased with age
 73   II,     5.  7.  7    |     Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al, Kidney
 74   II,     5.  7.  7    |              May;15(5):1300-6.~Stengel B, Billon S, van Dijk PC,
 75   II,     5.  7.  7    |               DJ, de LS, Van VJ, Klebe B, Middleton R, et al (2007):
 76   II,     5.  7.  7    |           Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok
 77   II,     5.  8.  7    |                 Flodin R, and Järvholm B (2004): Increased mortality
 78   II,     5.  8.  7    |         Neukirch F, Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire
 79   II,     5.  8.  7    |               59: 120125.~ ~Detournay B, Pribil C, Fournier M, Housset
 80   II,     5.  8.  7    |          Pribil C, Fournier M, Housset B, Huchon G, Huas D, Godard
 81   II,     5.  8.  7    |        Ericsson A, Jonsson E, Lundback B (2002): Costs of COPD in
 82   II,     5.  8.  7    |                E, Larsson LG, Lundback B. (2006): Prevalence and
 83   II,     5.  8.  7    |                R, Larsson LG, Lundback B (2005): Ten-year cumulative
 84   II,     5.  8.  7    |                   Lindberg A, Eriksson B, Larsson LG, Ronmark E,
 85   II,     5.  8.  7    |               E, Sandstrom T, Lundback B (2006): Seven-year cumulative
 86   II,     5.  8.  7    |             367: 1747-1757.~ ~Lundback B, Lindberg A, Lindstrom M,
 87   II,     5.  8.  7    |               Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ,
 88   II,     5.  8.  7    |             Egger P, Visick G, Thakrar B, Sykes J, Pride NB (2000):
 89   II,     5.  9.  7    |          Heinrich J Gehring U, , Jacob B, Richter K, Fahlbusch B,
 90   II,     5.  9.  7    |                B, Richter K, Fahlbusch B, Schlenvoigt G, Bischof
 91   II,     5.  9.  7    |         conceptual issues. In: Spilker B Editors. Quality of Life
 92   II,     5. 10.  5    |             Fish and products thereof (b)~- Peanuts and products
 93   II,     5. 10.  5    |                alcoholic beverages.~ ~(b) fish gelatine used as carrier
 94   II,     5. 10.  7    |            DunnGalvin A,. Hourihane JO'B, Cornelisse-Vermaat JR,
 95   II,     5. 10.  7    |             DunnGalvin A, Hourihane JO'B, Frewer L, Knibb RC, Oude
 96   II,     5. 11.  3    |           including mild cases)~Meding B, et al~ ~Swedish school
 97   II,     5. 11.  3    |                13 to 20% in the 1980s (B Larsson-Stymne and L Widström,
 98   II,     5. 11.  3    |             contact allergy to cobalt (B Larsson-Stymne and L Widström,
 99   II,     5. 11.  3    |                with the law standards (B Bocca et al, 2007). Similarly,
100   II,     5. 11.  3    |           Medicine 1999;14(6):379385.~B Larsson-Stymne, L Widstrom,
101   II,     5. 11.  7    |              30:35-9.~ ~Larsson-Stymne B, Widstrom L (1985): Ear
102   II,     5. 11.  7    |          eczema eds T Ruzicka, J Ring, B Pryzbilla). London: Springer-Verlag,
103   II,     5. 11.  7    |                K, Krakauer R, Wanscher B (1980): Prevalence of skin
104   II,     5. 12.Acr    |           European Union~HBV~Hepatitis B virus~HCV~Hepatitis C virus~
105   II,     5. 12.  1    |               disease, i.e., hepatitis B and C virus (HBV and HCV)
106   II,     5. 12.  3    |               in Figures 5.12.1 (A and B) and 5.12.2 (A and B).~ ~ ~ ~
107   II,     5. 12.  3    |               and B) and 5.12.2 (A and B).~ ~ ~ ~Table 5.12.1 gives
108   II,     5. 12.  4    |               disease, i.e., hepatitis B and C virus (HBV and HCV)
109   II,     5. 12.  7    |              Mele A, Ortolani G, Adamo B, Rapicetta M, Forte P,~Pisani
110   II,     5. 12.  7    |          Pisani A, Soldo L, Sarrecchia B, et al (1989): Decline in
111   II,     5. 12.  7    |            exposure to hepatitis A and B infections in children in
112   II,     5. 12.  7    |          Mantion G, Messner M, Launois B, Samuel D, Cherqui D, et
113   II,     5. 12.  7    |          Margolis HS (1990): Hepatitis B epidemiology and prevention.
114   II,     5. 12.  7    |          changing pattern of hepatitis B virus infection over the
115   II,     5. 14.  2    |               years of age surveyed.~ ~b. Dental Contact within the
116   II,     5. 15.  6    |               2007)~Wastfelt M, Fadeel B, Henter JI. A journey of
117   II,     6.Acr        |          Response System~HBV~Hepatitis B Virus~HCAI~Health Care Associated
118   II,     6.Acr        |            Haemophilus Influenzae type B~HPV~Human Papilloma Virus~
119   II,     6.  3.  3    |            section addresses hepatitis B and C.~ ~Hepatitis B~ ~Hepatitis
120   II,     6.  3.  3    |         hepatitis B and C.~ ~Hepatitis B~ ~Hepatitis B is an infection
121   II,     6.  3.  3    |                Hepatitis B~ ~Hepatitis B is an infection of the liver
122   II,     6.  3.  3    |              liver caused by hepatitis B virus (HBV). HBV can result
123   II,     6.  3.  3    |                transmission. Hepatitis B has to be considered increasingly
124   II,     6.  3.  3    |             180 000 cases of Hepatitis B were reported in Europe
125   II,     6.  3.  3    |                have included hepatitis B vaccine in their national
126   II,     6.  3.  3    |           incidence of acute hepatitis B infection had been declining
127   II,     6.  3.  4    |               by influenza virus A and B. Each year there are epidemics
128   II,     6.  3.  4    |              for the season. Influenza B viruses were co-circulating
129   II,     6.  3.  4    |            countries the proportion of B viruses was higher than
130   II,     6.  3.  5    |            Haemophilus influenzae type b in the countries that have
131   II,     6.  3.  5    |                is caused by serogroups B and C. Since 1999, several
132   II,     6.  3.  5    |              vaccine against serogroup B disease.~ ~Since 1999, countries
133   II,     6.  3.  5    |            Haemophilus influenzae type b~ ~Haemophilus influenzae
134   II,     6.  3.  5    |            Haemophilus influenzae type b (Hib) is a respiratory tract
135   II,     6.  3.  7    |         military and laboratory staff. B. anthracis has been recorded
136   II,     6.  4.  5    |       occurrence of resistant strains; b) put in place and improve
137   II,     6.  4.  5    |   authorization to market antibiotics; b) support, at Community level,
138   II,     6.  4.  5    |               treatments and vaccines; b) support the development
139   II,     7.  3.  5    |            European Union (Figure 7.15.b. Suicide and intentional
140   II,     7.  3.  5    |            Figure 7.16).~ ~Figure 7.15.b. Suicide and intentional
141   II,     7.  4.  1    |             injury deaths (Figure 7.19.B).~ ~Figure 7.19.b. Fatal
142   II,     7.  4.  1    |          Figure 7.19.B).~ ~Figure 7.19.b. Fatal injuries by causes
143   II,     7.  7        |               on 15 April 2008].~ ~Guo B, Harstall C (2004). For
144   II,     8.  2.  1    |            Valk, H., Buono, S., Azema, B., Aussilloux, C., Määttä,
145   II,     8.  2.  2    |       Organization 86:6370.~Thylefors B, Négrel A-D, Pararajasegaram
146   II,     8.  2.  3    |              2003;42:18-28~ ~Karlsmose B, Lauritzen T, Parving A (
147   II,     9.  1.  1    |                82(2):257-61.~ ~Blondel B, Macfarlane A, Gissler M,
148   II,     9.  1.  1    |                   Draper ES, Manktelow B, Field DJ, James D (1999):
149   II,     9.  1.  1    |              452-60.~ ~Gould JB, Davey B, Stafford RS (1989): Socioeconomic
150   II,     9.  1.  1    |              2000;95(2):215-21.~ ~Kahn B, Lumey LH, Zybert PA, Lorenz
151   II,     9.  1.  1    |                92.~Kaminski M, Blondel B, Saurel-Cubizolles M-J (
152   II,     9.  1.  1    |              Platt RW, Yang H, Haglund B, Cnattingius S, Bergsjo
153   II,     9.  1.  1    |        Epidemiol 16(1):16-22.~ ~Langer B, Caneva MP, Schlaeder G (
154   II,     9.  1.  1    |               J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I (2006):
155   II,     9.  1.  1    |               2004;103(1):128-36.~Luke B, Brown MB (2007a). Elevated
156   II,     9.  1.  1    |               2007;22(5):1264-72.~Luke B, Brown MB (2007b). Contemporary
157   II,     9.  1.  1    |               84.~ ~Zeitlin J, Blondel B, Alexander S, Breart G (
158   II,     9.  1.  1    |         Alexander S, Barros H, Blondel B, et al (2003): Selecting
159   II,     9.  1.  2    |                anomaly in that country b) the level of investigation
160   II,     9.  1.  2    |             the baby is not viable. ~ ~b) Hospital Episode or Discharge
161   II,     9.  1.  2    |              infant death certificates b) the potential to link registry
162   II,     9.  1.  2    |              special susceptibility.~ ~b) Policies aimed at ensuring “
163   II,     9.  1.  2    |                     Busby A, Armstrong B, Dolk H, Armstrong N, Haeusler
164   II,     9.  1.  2    |               Latos-Bielenska A, Gener B, Portillo I, Addor M-C,
165   II,     9.  1.  2    |          Daltveit, A, Aneren G, Ollars B, Edwards G (2005a): "Preventing
166   II,     9.  1.  2    |          Abramsky L, Dolk H, Armstrong B and a EUROCAT Folic Acid
167   II,     9.  1.  2    |             Candela S, Dale I, Danaché B, De Vigan C, Fevotte J,
168   II,     9.  1.  2    |              Vigan C, Addor M-C, Gener B, Haeusler M, Jordan H, Tucker
169   II,     9.  1.  2    |           Scott JES, Addor MC, Botting B, de Vigan C, de Walle H,
170   II,     9.  1.  2    |               Nelen V, Bakker M, Gener B, Abramsky L, Addor M-C and
171   II,     9.  2.  3    |         leukaemias (Figures 9.2.1a and b). Leukaemia is often successfully
172   II,     9.  2.  7    |                 Lerner, R.M., Orlos, J.B., Knapp, J.R. (1976): Physical
173   II,     9.  3.  1    |            nature of the diseases and (b) those women with osteoporosis
174   II,     9.  3.  1    |                 G Klotz, T Reifenrath, B Mathers, M Engleman, U (
175   II,     9.  3.  2    |                82(2):257-61.~ ~Blondel B, Macfarlane A, Gissler M,
176   II,     9.  3.  2    |                   Draper ES, Manktelow B, Field DJ, James D (1999):
177   II,     9.  3.  2    |              452-60.~ ~Gould JB, Davey B, Stafford RS (1989): Socioeconomic
178   II,     9.  3.  2    |             2004;103(3):551-63.~ ~Kahn B, Lumey LH, Zybert PA, Lorenz
179   II,     9.  3.  2    |              92.~ ~Kaminski M, Blondel B, Saurel-Cubizolles M-J (
180   II,     9.  3.  2    |              Platt RW, Yang H, Haglund B, Cnattingius S, Bergsjo
181   II,     9.  3.  2    |                14(3):194-210.~ ~Langer B, Caneva MP, Schlaeder G (
182   II,     9.  3.  2    |               J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I (2006):
183   II,     9.  3.  2    |             the United Kingdom.~ ~Luke B, Brown MB (2007a). Elevated
184   II,     9.  3.  2    |             2007;22(5):1264-72.~ ~Luke B, Brown MB (2007b). Contemporary
185   II,     9.  3.  2    |        Marchand L, Pierrat V, Larroque B, et al (2007): Neonatal
186   II,     9.  3.  2    |               84.~ ~Zeitlin J, Blondel B, Alexander S, Breart G (
187   II,     9.  3.  2    |         Alexander S, Barros H, Blondel B, et al (2003): Selecting
188   II,     9.  3.  3    |            Bajos N, Wadsworth J, Ducot B, Johnson AM, Le Pont F,
189   II,     9.  3.  3    |           Johnson AM, McManus S, Erens B (2001): Measuring sexual
190   II,     9.  3.  3    |             Johnson A, Mercer C, Erens B, et al (2001): Sexual behaviour
191   II,     9.  3.  3    |            1835-42.~Kangas I, Andersen B, McGarrigle CA, Østergaard
192   II,     9.  3.  3    |          Macdowall W, McManus S, Erens B, Mercer CH, Johnson AM,
193   II,     9.  4.  7    |                   Rathmann W, Haastert B, Icks A et al (2005) The s.
194   II,     9.  5.  3    |              Kingdom (England & Wales) b ( 2000 data )~· 4.9% of
195   II,     9.  5.  3    |           European Women’s Lobby, 2001~b London Metropolitan University,
196   II,     9.  5.  3    |                University, 2003 ~ ~ ~ ~B. Information of domestic
197  III,    10.  1.  3    |               376-90.~Melzer K, Kayser B, Saris WHM, Pichard C (2005):
198  III,    10.  1.  3    |               91(11):1615-1621.~Rosner B (2000): Fundamentals of
199  III,    10.  2.  1    |          Cerveri I, Kerhof M, Leynaert B, Luczynska C, Neukirch F,
200  III,    10.  2.  1    |      References~ ~Anderson P, Baumberg B (2006): Alcohol in Europe:
201  III,    10.  2.  1    |         Heather N, Saunders J, Burnand B (2007): Effectiveness of
202  III,    10.  2.  1    |          School Children~HBV~Hepatitis B Virus~HCV~Hepatitis C Virus~
203  III,    10.  2.  1    |                IDUs there is hepatitis B. The prevalence of markers
204  III,    10.  2.  1    |          mainly HIV/Aids and hepatitis B and C) among drug users
205  III,    10.  2.  1    |               van Loveren C, Fernandes B, Seppa L, Athanassouli T.
206  III,    10.  2.  1    |         Norlund A, Petersson LG, Soder B. Caries preventive effect
207  III,    10.  2.  1    |              al, 2006) is available.~ ~b) Health behaviour in school-aged
208  III,    10.  2.  1    |                hours spent sitting).~ ~b) Comparability of data sources~
209  III,    10.  2.  1    |         Exercise, 26:857-865.~ ~Popkin B M, Duffey K, Gordon-Larsen
210  III,    10.  2.  1    |             listed under references.~ ~b) Food consumption and dietary
211  III,    10.  2.  1    |           Dietary-history~28~Mensink G B M et.al. (2004) Food and
212  III,    10.  2.  1    |               Health Nutr., 2001, 4, 5(B), p. 1183-1186~Portugal~
213  III,    10.  2.  1    |             Foz-Sala M, Moreno-Esteban B, for the Grupo Colaborativo
214  III,    10.  2.  1    |               Pudule I, Jēce I, Velika B, Grīnberga D, Villeruša
215  III,    10.  2.  1    |                Andersson M, de Benoist B, Darnton-Hill I, Delange
216  III,    10.  2.  1    |           Linseisen J, Schulz M, Hemon B, Riboli E (2002): Consumption
217  III,    10.  2.  1    |               Palmqvist R, Van Guelpen B, Bingham SA, McTaggart A,
218  III,    10.  2.  1    |         Klipstein-Grobusch K, San-Jose B, Welch AA, Krogh V, Luben
219  III,    10.  2.  4    |                 349: 969-974.~ ~Childs B, Valle D (2000): Genetics,
220  III,    10.  2.  4    |        Washington~ ~Gao J, Shan G, Sun B, Thompson PJ, Gao X (2006):
221  III,    10.  2.  4    |              EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch
222  III,    10.  2.  4    |           Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S,
223  III,    10.  3.  1    |            Tirmarche M, Caër S, Quesne B, Laurier D (2007): Lung
224  III,    10.  3.  1    |        McMichael T, Smith W, Armstrong B (2006) Prüss-Üstün A, Zeeb
225  III,    10.  3.  1    |             noise. Edited by: Berglund B, Lindvall T, Schwela D.~
226  III,    10.  3.  2    |                A Alimonti, F Petrucci, B Bocca, P Schramel, M Zischka,
227  III,    10.  3.  2    |           September 2005. htt ~ ~Vieth B, Rüdiger, R, Ostermann,
228  III,    10.  3.  2    |                 Rüdiger, R, Ostermann, B, Mielke, H. (2005): Rückstände
229  III,    10.  3.  3    |            Haemophilus influenzae type b~vCJD~Variant Creutzfeldt-Jakob
230  III,    10.  3.  3    |               by influenza virus A and B; each year there are epidemics
231  III,    10.  3.  3    |            Haemophilus influenzae type b (Hib) is a respiratory tract
232  III,    10.  3.  4    |              2007a~Menne, 2005~ ~Menne B, Ebi KL (Eds.)(2006): Climate
233  III,    10.  4.  1    |                 between scenario A and B above). Although this means
234  III,    10.  4.  2    |               additives, feed hygiene; b) animal health and welfare:
235  III,    10.  4.  2    |                a) risk assessment and (b) risk communication. Its
236  III,    10.  4.  2    |               requiring rapid action; (b) any recommendation or agreement
237  III,    10.  4.  2    |        Escherichia coli.~ ~Other 'list B' zoonoses should be included
238  III,    10.  4.  2    |               6.4 specified in Chapter B.I of Annex III of the TSE
239  III,    10.  4.  2    |               for nitrate (0-3.7 mg/kg b.w) and nitrite (0-0.07 mg/
240  III,    10.  4.  2    |              and nitrite (0-0.07 mg/kg b.w) (FAO/WHO, 2003). Exposure
241  III,    10.  4.  2    |        modified organisms (mainly Part B thereof);~· The placing
242  III,    10.  4.  2    |               appropriate. (EFSA, 2006 b)~ ~Emerging risk~ ~With
243  III,    10.  4.  2    | appropriateness of official controls; (b) that staff carrying out
244  III,    10.  4.  2    |            authorities to be engaged; (b) their powers and responsibilities;
245  III,    10.  4.  5    |               Figure 10.4.5.1.1. A and B) (EEA, 2008).~ ~Figure 10.
246  III,    10.  4.  5    |              water~ ~Figure 10.4.5.1.1.b. Bathing water. Compliance
247  III,    10.  4.  5    |          fourth assessment” (EEA, 2007 b), chapters on Sustainable
248  III,    10.  5.  1    |                capital and trust, and (b) increased levels of physical activity
249  III,    10.  5.  1    |               of urban conditions and (b) for the improvement of
250  III,    10.  5.  1    |               Change Biology.~Konlaan, B B. Bygren, L O. Johansson,
251  III,    10.  5.  1    |             Change Biology.~Konlaan, B B. Bygren, L O. Johansson,
252  III,    10.  5.  1    |               12.~Loftness V, Hakkinen B, Adan O, Nevalainen A (2007):
253  III,    10.  5.  1    |             Michaud C, Murray C, Bloom B (2001): Burden of disease
254  III,    10.  5.  1    |               2003, vol 93, p 288~Said B et al. Outbreaks of infectious
255  III,    10.  5.  3    |              Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J (
256  III,    10.  6.  1    |                7.~ ~Ganster DC, Victor B (1998). The impact of social
257   IV,    11.  1.  3    |               increasing cost sharing; b) introducing competition
258   IV,    11.  1.  6    |              doctor’s discretion); and b) referrals to specialists
259   IV,    11.  5.  4    |    Transmission of HIV/AIDS, hepatitis B and C, bacteria, fungi and
260   IV,    11.  5.  6    |             sense and sensitization by B Bradley and S Gore, Martinus
261   IV,    11.  6.  4    |              for their population; and b) adjusting the resource
262   IV,    11.  6.  4    |                insured population; and b) the size of their revenue
263   IV,    11.  6.  5    |             258.~ ~Burgers JS, Fervers B et al. (2004): "International
264   IV,    11.  6.  5    |          systems in Western Europe. R. B. Saltman, R. Busse and J.
265   IV,    11.  6.  5    |              Equity in Health.~ ~Gibis B, Koch-Wulkan PW et al. (
266   IV,    11.  6.  5    |          systems in Western Europe. R. B. Saltman, R. Busse and J.
267   IV,    11.  6.  5    |              care reform in Europe. R. B. Saltman, J. Figueras and
268   IV,    11.  6.  5    |                   Macinko J, Starfield B et al. (2003): "The contribution
269   IV,    11.  6.  5    |       Organization.~ ~McGrail K, Green B et al. (2000): "Age, costs
270   IV,    11.  6.  5    |         Blackwell Publishing.~ ~Merkel B, Hübel M (1999): Public
271   IV,    11.  6.  5    |          systems in Western Europe. R. B. Saltman, R. Busse and J.
272   IV,    11.  6.  5    |          Policy 6: 145-50.~ ~Starfield B, Shi L et al. (2005): "The
273   IV,    11.  6.  5    |                   Taggiasco , Sarrut B et al. (1992): "European
274   IV,    12.  1        |        stringent protective measures;~(b) by way of derogation from
275   IV,    12.  5        |                HLY was awarded a grade B. The two main issues were
276   IV,    12. 10        |                National/Regional~ ~ ~ ~B) Actions adopted in relation
277   IV,    12. 10        |       physical activity is included.~ ~B. "6 a day" consists of an
278   IV,    12. 10        |            Koch-Institute (see www. ~ ~B) Actions adopted in relation
279   IV,    12. 10        |        launched on June 16th 2008.~ ~ ~B) Actions adopted by Member
280   IV,    12. 10        |               diseases (i.e. Hepatitis B & C, HPV, Syphilis, and
281   IV,    12. 10        |       Prevention Plan 2005-2007.~ ~ ~ ~B) Actions adopted in relation
282   IV,    12. 10        |              working in this area.~ ~ ~B) Actions adopted in relation
283   IV,    12. 10        |           condom during the last month~B: had sex without a condom "
284   IV,    12. 10        |      determinants~No indicator~ ~ ~ ~ ~B) Actions adopted in relation
285   IV,    12. 10        |     determinants~ Intermediate~ ~ ~ ~ ~B) Actions adopted in relation
286   IV,    13.  4        |                ESF regulation art. 3.1(b)) provides for: "specific
287   IV,    13.  9        |              Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J (